newsfilter
← Earnings
Earnings Releases·

PDS Biotechnology — Third Quarter 2026 Earnings Summary

  • Reported a net loss of $7.6 million ($0.11/share) for Q3 2026, a reduction from $9.0 million ($0.19/share) in the prior year period, driven by a $2.2 million decrease in total operating expenses.
  • Cash and cash equivalents declined to $15.2 million as of September 30, 2026, from $26.7 million at year-end 2025, while long-term debt was fully eliminated.
  • Completed an initial PIPE financing closing of up to $22.3 million led by Nant Capital, LLC, with a contingent milestone closing tied to an FDA Phase 3 protocol submission for PDS0301.
  • Strategic focus shifted to PDS0301 as the lead program, while PDS0101 received new patents in Japan, India, and Israel and entered an option agreement for an exclusive license negotiation with NantWorks.
  • Expanded the Board of Directors with three new members effective October 18, 2026, and appointed Nant Capital designees to oversee future strategic partnerships for PDS0101 Phase 3 development.
Company
PDS BIOTECHNOLOGY CORP
Sector
Healthcare
Industry
Biotechnology